Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

EffRx, Nycomed announce European filing for EX101 marketing approval

EffRx Pharmaceuticals SA and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.

21 Sep 2010

Recommendations for prostate cancer prevention and treatment

In light of Prostate Cancer Awareness month, integrative medicine pioneer and cancer expert Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer. As a well known specialist in the field of integrative prostate cancer therapy, Dr. Eliaz strategically combines ancient and modern healing modalities into a holistic practice of medicine by successfully incorporating the most effective and well researched therapies available in conventional and complementary medicine.

21 Sep 2010

FG-4592 oral anemia therapy receives CTA approval from SFDA

FibroGen, Inc., today announced that its investigational oral anemia therapy, FG-4592, received Clinical Trial Application (CTA) approval from the Chinese State Food and Drug Administration (SFDA) to commence clinical development for the treatment of anemia associated with chronic kidney disease (CKD) in the People's Republic of China.

21 Sep 2010

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Lisofylline drug effective for Type 2 diabetes

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

20 Sep 2010

Improper biological clocks tend to develop diabetes, obesity: Research

Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice.

20 Sep 2010

BRCA1 gene mutation increases breast cancer risk: Research

Individuals with disrupting mutations in the BRCA1 gene are known to be at substantially increased risk of breast cancer throughout their lives. Now, discoveries from an international research team led by Mayo Clinic researchers show that some of those persons may possess additional genetic variants that modify their risk. These new findings enhancing individualized medicine appear in the current Nature Genetics.

20 Sep 2010

Scientists discover new genetic variants, pave way for early detection of ovarian cancer

An international consortium of scientists has discovered new genetic variants in five regions of the genome that affect the risk of ovarian cancer in the general population, according to two separate studies published today (Sunday), online in Nature Genetics.

20 Sep 2010

Emisphere’s SNAC drug successful in reducing food intake; increasing satiety

Emisphere Technologies, Inc. today announced that a clinical study found that the company's proprietary oral SNAC (Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") additive, in combination with two digestive hormones, was successful in reducing food intake and increasing satiety in healthy male subjects.

18 Sep 2010

Spike mat reduces muscle tension pain: Study

Spike mats do not alleviate chronic pain. Nor do they lead to a better night's sleep. But pain sufferers who have tested a spike mat did experience a measurable reduction in the worst peaks of pain. This is shown in a research study performed at Karlstad University in Sweden.

17 Sep 2010

Scientists discover simple molecular test to block GOAT enzyme

Scientists at The Scripps Research Institute have designed a new molecular test that will allow researchers to look for potential drugs targeting a human metabolic enzyme believed to stimulate the appetite and play a role in diabetes.

17 Sep 2010

Artificial pancreas for diabetics

In another few years diabetics may be treated using an artificial pancreas developed by Professor Joan Taylor professor of Pharmaceutics at De Montfort University (DMU), Leicester. This could mean freedom from daily insulin injections she said.

16 Sep 2010

Hormone Foundation produces two fact sheets to dispel myths of adrenal fatigue, Wilson's temperature syndrome

The Hormone Foundation, the public education affiliate of The Endocrine Society, has produced two new fact sheets to dispel myths about so-called "diseases" popularized through the Internet: adrenal fatigue and Wilson's temperature syndrome.

16 Sep 2010

Study finds GRK2 molecule promotes cell death after heart attack

A molecule known to be involved in progressive heart failure has now been shown to also lead to permanent damage after a heart attack, according to researchers at Thomas Jefferson University.

16 Sep 2010

Calm men preferred by women: Study

According to a new study, women prefer calm men to stressed ones. Researchers at the University of Abertay Dundee in Scotland found that women were more attracted to calm, collected men with lower levels of the stress hormone cortisol coursing through their systems, than men who are chronically stressed. The study was published in the Proceedings of the Royal Society B journal. The researchers also found that there was no clear association between attractiveness and high levels of testosterone as was thought before.

16 Sep 2010

NPS Pharmaceuticals intends to offer public offering of common stock

NPS Pharmaceuticals, Inc. today announced that it intends to offer and sell approximately $41,290,000 of its common stock in an underwritten public offering.

16 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Heart patients with Type D personality at higher risk of future cardiovascular problems

Heart patients with the "distressed" (Type D) personality profile may face a higher risk of future cardiovascular problems, according to a summary article published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

15 Sep 2010

UT Southwestern receives $8 million NIH grant to study influence of brain and liver on inflammation

An $8 million grant from the National Institutes of Health will enable UT Southwestern Medical Center to investigate how fat tissue "talks" to the brain and the liver to promote inflammation-related disorders such as diabetes, heart disease and obesity.

15 Sep 2010